

Oral CBD treatment is associated to an anti-inflammatory gene expression signature in myeloid cells of people living with HIV

Simone Marini^{1,2*}, Amanda Huber³, Melanie N. Cash^{2,4}, Marco Salemi^{2,4}, Robert L Cook^{1,4}, Paul Borsa⁵, and Carla Mavian^{2,4*}.

*Corresponding authors: simone.marini@ufl.edu; cmavian@pathology.ufl.edu

1 Department of Epidemiology, University of Florida

2 Department of Pathology, Emerging Pathogens Institute, University of Florida

3 Department of Radiation Oncology, University of Michigan

4 Emerging Pathogens Institute, University of Florida

5 Department of Applied Physiology & Kinesiology, University of Florida

Abstract (short)

HIV-related comorbidities appear to be related to chronic inflammation, a condition characterizing people living with HIV (PLWH). Prior work indicates that cannabidiol (CBD) might reduce inflammation; however, the genetics underpinning this effect are not well investigated. Our main objective is to detect gene expression alterations in human peripheral blood mononuclear cells (PBMCs) from PLWH after at least one month of CBD treatment.

We collected PBMCs from three HIV-positive subjects at baseline and after CBD treatment (at least 27 days) via single-cell RNA sequencing. We obtained a coherent signature, characterized by an anti-inflammatory activity, of differentially expressed genes in myeloid cells.

Our study shows how CBD is associated with alterations of gene expression in myeloid cells after CBD treatment.

1. Introduction

Despite the advent of combined antiretroviral therapy (cART), residual HIV replication persists and is associated with low-level immune activation driving chronic inflammation, one of the main HIV-related complications. HIV patients experience non-AIDS-related complications that are typical of older patients, such as presence of neurocognitive disorders, metabolic syndrome, bone abnormality, non-HIV-associated cancers, and neurocognitive disorders¹. Chronic inflammation is a mechanism broadly involved in a plethora of diseases affecting aging patients. Experts explicitly name this condition as *inflammageing*². Inflammageing is a pivotal risk factor for dementia, chronic kidney disease, diabetes mellitus, cancer, depression, cardiovascular diseases, and sarcopenia.

While the main HIV reservoir is known to be in resting memory CD4+ T-cells, several studies have shown that a fraction of viral variants, detected either in residual viremia during therapy or at rebound after therapy interruption, is genetically distinct from virus present in T-cell subsets³⁻⁵. Myeloid cells, particularly monocytes and macrophages, have been described as active reservoirs driving persistent low-level HIV expression and contributing to viral replication during rebound⁶⁻¹⁰. Monocytes are chronically activated during HIV infection, and are major mediators for the development of comorbidities related to inflammageing, and specifically cardiovascular diseases, neurocognitive disorder, and aging of the innate immune system^{11,12}. Residual HIV viremia is likely a source of monocyte activation as HIV proteins, such as p17, induce the production of proinflammatory molecules by activated monocytes¹³. Inflammatory mediators produced by monocytes, but not T-cell activation, predict low levels of chronic immune activation that persist during cART treatment, a process named serious non-AIDS events during viral suppression on cART^{14,15}, highlighting the important role of monocyte activation during cART-treated HIV infection.

Cannabis sativa is widely used for medical purposes and has anti-inflammatory activity. Cannabis sativa and its cannabinoid derivatives, Δ^9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), are largely used by people living with HIV (PLWH) to stimulate appetite, prevent weight loss (FDA approved Marinol or Dronabinol), or manage chronic pain. CBD does not have psychoactive effects and CBD products are available over the counter in the US. CBD is a compound investigated for its beneficial effect on inflammation¹⁶⁻¹⁸; but despite its widespread use, the impact of CBD on health outcomes in PLWH remains understudied¹⁹. Here we investigate the hypothesis that CBD is associated with a reduction of the expression of pro-inflammatory genes in PBMCs of HIV-positive subjects via single-cell RNA sequencing (scRNAseq).

Our results show a gene expression signature associated with CBD in myeloid cells. Importantly, the great majority of these genes are known to be inflammation promoting.

2. Results

We sequenced six blood samples from three HIV-positive subjects (SUB1, SUB2, SUB3): for each subject, we included a baseline (pre-CBD treatment) and a post-CBD treatment (27-60 days, ~67mg/day).

We identified eight distinct cell populations based on their expression profiles. We used the Seurat package²⁰ for downstream analysis, applied after obtaining the results from 10x Genomics Cell

Ranger 3.0.0. Details of the procedure are reported in the Methods. After quality control, we obtained 30,339 cells expressing 41,198 genes. Unsupervised clustering revealed 10 cell clusters (Figure 1, A). Per-subject projection confirms that cells from each subject are present in all the clusters (Figure 1, B), while per-condition projection shows an apparent structural effect on the UMAP-projected cells of clusters 5 and 7 (Figure 1, C).

We labeled the clusters based on specific overexpressed genes (Figure 2), obtaining seven cell populations (Figure 1, D): CD4 T cells (cluster 0; 8,622 cells expressing *IL-7R*, *LEF1*, *CD28*, but not *CD8A*); CD8 T cells (clusters 1 and 2; 11,303 cells expressing *CD8A*); NKT cells (clusters 3 and 8; 4,279 cells expressing *NKG7*, *KLRD1*, *KLRG1*, and *CD8A*); NK cells (cluster 4; 3,223 cells expressing *NKG7*, *KLRD1*, *KLRG1*, but not *CD8A*); Myeloid cells, including monocytes (clusters 5 and 7; 2,277 cells expressing *LYZ*, *CD14*, *S100A8*, and *S100A9*); B cells (cluster 6; 595 cells expressing *CD79A* and *CD79B*); and plasmablasts/plasma cells (cluster 9; 40 cells, expressing *JCHAIN*, *IGHG1*, *IGHA1*, *IGHA2*).




Figure 1. UMAP projection of the dataset. (A) Unsupervised clustering finds 10 cell clusters, numbered 0 to 9. (B, C) Per-subject and per-condition colored projections. (D) Cell populations labeled based on overexpressed genes in the clusters.




Figure 2. Gene expression violin plots for genes of interest to label cell clusters into populations: Cluster 0, CD4 T cells; clusters 1 and 2, CD8 T cells; clusters 3 and 8, NKT cells; cluster 4, NK cells; clusters 5 and 7, myeloid cells, including monocytes; cluster 6, B cells; and cluster 9, plasmablasts/plasma cells.

Myeloid cells carry a CBD-associated anti-inflammatory gene expression signature. We identified six differentially expressed genes (DEGs) in myeloid cells, reported in Table 1. All the DEGs are underexpressed after CBD treatment. Five out of six genes show a positive role in the inflammation process: *CXCL8* (interleukin-8) is a member of the chemokine family involved in cell recruitment and activation under inflammatory conditions²¹; *EREG* is a pro-inflammatory gene with a role in tissue healing and vascularization²²; *JUN* and *FOS* are two genes expressed in monocytes and macrophages involved in promoting inflammation^{23,24}, and both are included as markers in a recently general inflammatory macrophage activation phenotype encompassing responses to HIV, sepsis, and SARS-CoV-2²⁵; *CCL3* is a pro-inflammatory gene and one of the major HIV-suppressive factors produced by CD8+ T-cells and monocytes^{25,26}. Other proinflammatory genes appear among the top underexpressed genes (Table 1): *GPR183* plays a role in attracting macrophages during viral inflammation²⁷; *MIR23AHG* is a long non-coding RNA gene promoting inflammation polarization in macrophages²⁸ and associated to chronic inflammation in ulcerative colitis²⁹; *TIPARP* is an antiviral gene, with a specific anti-HIV-1 effect in monocytes³⁰; *NAMPT* is a gene involved in the inflammatory responses activation with cytokine-like behavior³¹; *IL1B* is a pro-inflammatory cytokine^{32,33}; and *KLF6* is known to regulate macrophage polarization towards the proinflammatory phenotype³⁴. In summary, five out of six DEGs and several of the top underexpressed genes are markedly involved in inflammatory processes of myeloid cells. Their underexpression in concert can therefore be interpreted as an anti-inflammatory signature associated with the CBD treatment.

Gene	<i>log2FC</i> (all)	<i>log2FC</i> SUB1	<i>log2FC</i> SUB2	<i>log2FC</i> SUB3	<i>Fraction</i> <i>Baseline</i> (all)	<i>Fraction</i> <i>CBD</i> (all)	<i>P-value</i> (adj., all)
CXCL8	-1.78	-2.03	-2.03	*	0.558	0.344	0
EREG	-1.72	-1.87	-1.92	-0.83	0.304	0.149	0
PLEKHG2	-1.53	-1.92	-1.62	-0.63	0.571	0.21	0
G0S2	-1.24	-1.76	-0.14	0.15	0.21	0.21	1.27E-253
JUN	-1.23	-1.38	-0.83	-1.07	0.899	0.732	0
FOS	-1.15	-1.62	-1.16	-0.35	0.998	0.985	0
<i>GPR183</i>	-1.08	-1.42	-0.69	-0.39	0.427	0.21	1.82E-219
<i>MIR23AHG</i>	-1.06	-1.34	-0.96	-0.45	0.831	0.918	0
CCL3	-1.04	-1.32	-1.38	-0.39	0.366	0.174	6.62E-184
<i>TIPARP</i>	-1.04	-1.35	-0.88	-0.35	0.717	0.512	8.33E-275
ABCA1	-1.02	-1.46	-0.43	-0.35	0.646	0.418	1.6e-254
ENSG00000287124	-0.99	-1.06	-0.77	-0.73	0.645	0.501	1.33E-241
<i>NAMPT</i>	-0.98	-1.52	-0.47	*	0.986	0.989	0
ENSG00000253736	-0.97	-1.03	-1.01	-0.84	0.926	0.793	1.85E-301
<i>IL1B</i>	-0.96	-0.94	-1.76	-0.43	0.536	0.364	1.08E-269
<i>KLF6</i>	-0.96	-1.12	-1.01	-0.46	0.984	0.971	0
ANKRD28	-0.91	-0.97	-1.52	-0.28	0.601	0.402	1.83E-171

Table 1. Top underexpressed genes in myeloid cells ($\log_2FC < -0.9$, considering cells from all the subjects). **Bold:** DEGs; *italics:* genes of interest; \log_2FC = base-2 logarithm of the fold change (CBD versus baseline); Fraction baseline = fraction of cells expressing the gene at baseline; Fraction CBD = fraction of cells expressing the gene after CBD treatment; P-value (adj.) = FDR adjusted p-value; values reported as * imply a \log_2FC within the [-0.1, 0.1] interval.

STRING analysis indicates the DEG signature includes a protein interaction module. Using our DEGs as input in the STRING database, a collection of known protein interactions³⁵, with highest stringency for the interaction score, we obtained a structured protein interaction module centered on *JUN* and including five out of six genes (p-value 0.0001, Figure 3).

GO-based scoring and serology suggest a general anti-inflammatory shift in myeloid cell gene expression. To further confirm the anti-inflammatory shift in myeloid cells, we designed an inflammation score based on the gene expression of all the genes expressed in our dataset that are listed under the Gene Ontology term *Positive regulation of inflammatory response* (GO:0050729). The score decreases 12% after CBD in myeloid cells, from a median of 0.225 at baseline to a median of 0.198 (p-value = 9.538e-08, Kolmogorov-Smirnov test). This decrement is conserved by analyzing the score distribution per subject, as depicted in Figure 4, i.e., in SUB1, from 0.169 to 0.157, p-value

= 0004226; in SUB2 from 0.147 to 0.05, p-value = 6.741e-08; and in SUB3 from 0.13 to 0.102, p-value = 3.524e-05.

The general reduction in inflammation is also indicated serologically. More specifically, the decline in c-reactive protein (CRP) measure (baseline versus post-CBD treatment) was 10.25 and 8.2 for SUB1, 1.4 and 0.79 for SUB2, 2.56 and 0.88 for SUB3. The decline in erythrocyte sedimentation rate 32 and 30 in SUB1, 13 and 10 in SUB2, 12 and 4 in SUB3.




Figure 3. The coherent nature of the anti-inflammatory protein module (DEGs in CBD versus baseline) is confirmed as five out of six DEG show interactions in the STRING database analysis, most stringent interaction threshold, p-value 0.0001.




Figure 4. Violin and box plots of the inflammation score, per subject. The inflammation score is calculated with the genes of GO:0050729 (Positive regulation of inflammatory response).

Differentially expressed genes in other cell populations. Generally, non-myeloid cell populations did not show differentially expressed genes, with the exception of B cells, where we found *GNLY* underexpressed after CBD. *GNLY* is a cytotoxic gene that is typically expressed in NK and T cells³⁶. *GNLY* has shown the ability to promote the differentiation of monocytes into dendritic cells, and is known for its marked inflammatory role^{36,37}. Its decreased expression in the B cell population is in line with a general shift towards a less pro-inflammatory gene expression profile.

3. Discussion and Conclusions.

In this study, we measured gene expression at the single-cell level in PBMC samples obtained from three HIV-positive subjects before (baseline) and after 27 to 60 days of CBD oil treatment. Our data indicate that CBD treatment is associated with decreased expression of a pro-inflammatory myeloid cell gene signature in PLWH on cART.

The CBD dosage of this study is the dosage recommended by the CBD oil manufacturer, and is significantly lower than the one administered in other CBD clinical studies addressing, for example, psychosis or seizures³⁸. Of note, the CBD oil used in this study is hemp-derived and therefore different from purified synthetic CBD such as Epidiolex.

This study does not come without limitations: We process data for subjects with different lengths of CBD exposure; and SUB3 did not follow the treatment as diligently as SUB1 and SUB2. This seems to be reflected in the gene expression pattern (Table 1), where SUB1 and SUB2 show more marked and uniform effects. However, the gene expression variation in SUB3 seems to be in line with the other subjects, with 14 out of the top 17 underexpressed genes following the same trends. Furthermore, the anti-inflammatory shift in myeloid cell gene expression in SUB3 is also supported by the GO-based score (Figure 4) and the reduction in CRP and erythrocyte sedimentation.

While this study helps understand the genetic underpinning of CBD anti-inflammatory action, and the potential of its anti-inflammatory effects, the molecular chain leading to inflammation reduction remains to be unveiled. In future studies, we aim to target the extracted gene signature to better characterize it, along with its molecular interactors and a measure of HIV viral load.

4. Methods

Recruitment. All subjects were recruited according to a UF IRB-approved protocol and informed consent. *Main inclusion criteria included:* be older than 21 and younger than 60; be HIV+ and under antiretroviral therapy for 5+ years; report suppressed viral load in their most recent check-up; tests negative for THC; and be practicing birth control. *Main exclusion criteria included:* be suffering from conditions or taking medications that may impair the immune response; be pregnant; be a current marijuana or CBD user; be taking anti-seizure medicines; having any history of seizure disorder or head trauma; hepatic/liver disease or renal disease; or cardiovascular disease.

CBD treatment. CBD oil was provided by SunFlora, Inc, 411 19th Street South, St. Petersburg, FL 33712. SunFlora is a third-party tested hemp-derived product manufacturing company. The research team modified an existing FDA IND from SunFlora for this study. The hemp-extract (SunMed™ Hemp

Supplement) is a full spectrum CBD-rich formulation (~4-7%) containing very low levels of THC (<0.3%), along with all naturally occurring cannabinoids, terpenes, and essential oils from the plant extract. Flavoring agents have been added to ensure palatability. The tincture solution is provided in a 30mL bottle (2000mg CBD). Each subject was provided two bottles, each with a syringe dropper with instructions to administer the solution under the tongue twice per day (BID), 8-12 hours apart (morning and evening) with food at the prescribed daily dosage (1ml or ~67mg of CBD/day).

Sample collection. We sequenced six blood samples from three HIV-positive subjects: SUB1, SUB2, SUB3. Two samples are included in this study for each subject: a baseline (pre-CBD treatment) and a post-CBD treatment. The post-CBD treatment sample was taken after 27 days of treatment for SUB1, with ~8% missed doses; after 70 days for SUB2 (total 60 days of treatment), with ~6% missed doses; and after 29 days for SUB3m with ~60% missed doses. The planned treatment was 60 days, however, it was not possible to consider samples after the first 30 days from SUB1 and SUB3. Sedimentation Rate and CRP were obtained through the lab services of the UF Health Shands Hospital.

Single-cell extraction and sequencing. *PBMC extraction:* Blood was collected in vacutainer EDTA tubes and centrifuged within 30 minutes of collection at 200 x g for 10 minutes to separate plasma and cellular fraction. Blood fraction was diluted with an equal amount of wash buffer (Phosphate buffered saline [137 mM NaCl, 2.7 mM KCl, 8 mM Na₂HPO₄, and 2 mM KH₂PO₄]; 1mM EDTA) and mixed by inversion 5 times. Diluted blood was carefully layered over Lymphoprep Separation Media (Cellgro, Lincoln, NE) by gravity release. Tubes were centrifuged at 400 x g for 30 minutes in a swinging bucket centrifuge with brake off. The PBMC layer was collected, and cells were washed twice with wash buffer upon centrifugation at 400 x g for 10 minutes at room temperature with brake on. Next, cells were subjected to a lower speed wash at 200 x g for 10 minutes. Cells were filtered in a 70µm strainer (Fisher, Hampton, NH), counted and frozen down using CryoStor Freezing Medium (Stem Cell Technologies, Vancouver, BC, Canada) at ~15 million PBMCs per patient until they could be used for single-cell sequencing. *Sample preparation for single-cell RNA sequencing:* Cryopreserved human peripheral blood mononuclear cells (PBMCs) were prepared for 10x Genomics® Single Cell Sequencing according to the manufacturer's protocol (Pleasanton, CA) with a few modifications. Briefly, the cells were quickly thawed at 37°C following dropwise addition of warm complete medium (10% FBS in DMEM (Fisher)). Following centrifugation, cells were washed once again with complete medium before being subjected to dead cell removal using the Dead Cell Removal Kit (Miltenyi Biotec, Waltham, MA) according to the manufacturer's protocol. Next, the cells were pelleted and washed with PBS, 0.04% BSA (400 µg/mL) twice before filtering through a Flowmi™ Tip Strainer (Fisher) and counted to resuspend the cells at 1200 cells per µL for viability testing and library preparation. *Library construction and sequencing:* The 10x Chromium Controller and Single Cell 3' Library & Gel Bead Kit v3 (10X Genomics) were used to construct barcoded single-cell RNA-Seq libraries following the manufacturer's user guide (10X Genomics). Briefly, approximately 10,000 single cells at 90% or greater viability are loaded onto the Chromium Controller. Single cells are captured into Gel Bead-In Emulsions (GEM) where cell lysis and cDNA synthesis occur. All cDNAs produced from a single cell will contain a unique DNA molecular barcode. Following demulsification, mRNA-derived are recovered using SPRIselect reagent (Beckman). Library construction was performed by fragmentation, end repair, A-tailing, adaptor ligation, and sample index PCR, to which Illumina sequencing barcodes were added. After Ampure Beads clean up, libraries

were quantified by using Agilent TapeStation 4200 and qPCR quantification with NEB Library Quanti Kit for Illumina (NEB). *Sequencing*: The libraries were sequenced on an Illumina NovaSeq 6000 instrument using the S4 Reagent Kit v1.5, and aiming for 85,000 reads per cell. We obtained $6,202.5 \pm 1,604.09$ cells per sample, and $572,746,422 \pm 183,985,985$ reads per sample (Table 2). Count matrices were obtained with 10x Genomics Cell Ranger Single Cell Software Suite. Library preparation and scRNASeq were performed at the UF Interdisciplinary Center for Biotechnology Research (ICBR), University of Florida (UF). All quality control measures were in the normal range.

<i>Subject</i>	<i>Condition</i>	<i>Total cells (CellRanger)</i>	<i>Total cells (after QC)</i>	<i>Total reads/sample</i>
SUB1	Baseline	5,356	4,335	501,043,269
SUB1	CBD	5,435	3,766	417,536,116
SUB2	Baseline	5,312	4,581	489,280,870
SUB2	CBD	4,600	3,811	443,078,996
SUB3	Baseline	8,991	7,547	891,314,194
SUB3	CBD	7,521	6,299	694,225,088

Table 2. Total cells and reads per sample.

Single-cell downstream analysis. Data and code to obtain our results is available on github (https://github.com/smarini/CBD_HIV_scRNAseq) and based on Seurat v4.2.0²⁰. Where not indicated, parameters were used at their default values. Briefly, we merged the six samples and proceeded with quality control based on: number of different genes expressed per cell, counts per cell, and fraction of mitochondrial content per cell. We retained all the cells expressing more than 750 genes and less than 5000, and with a mitochondrial fraction lower than 0.15. We normalized the data and extracted the variable features, then scaled the data regressing against the fraction of the mitochondrial content. We ran a PCA on the scaled data, and used the first 25 components to calculate the UMAP projection and the neighboring cells. Clusters were extracted with the Louvain algorithm (resolution = 0.1).

Differential gene expression was calculated with a Poisson model, minimal fraction of cells expressing the gene = 0.25 and module of the base-2 logarithm of the fold change, $|\log_2FC| > 0.5$. For CBD signatures, we considered as DEGs the genes showing $|\log_2FC| > 1$, i.e., an expression at least doubled or halved when comparing conditions, both globally (i.e., considering the merged data set) and in at least two out of three subjects (i.e., considering cells from a single subject).

Inflammation score. We used the Seurat function `AddModuleScore` to calculate the inflammation score. We based the score on the genes listed in the GO term *positive regulation of inflammatory response* (GO:0050729), considering genes that are expressed in our data (101 genes total). Briefly, this score is based on the average expression levels of the GO genes, subtracted by the aggregated

expression of a control set of 100 randomly selected genes. To make the expression levels comparable, genes are binned based on averaged expression (24 bins).

STRING database analysis. We used our six myeloid cell DEGs as the input for a STRING (v. 11.5) analysis. To calculate the p-value, we proceeded empirically, as follows: We considered all the human protein-protein interactions of STRING (~20 thousand proteins involved in ~12 billion interactions); we iteratively extracted 6 random genes, and counted how many interactions were present in the subset with a score ≥ 0.9 , the threshold of our analysis. If the random subset had 4 or more interactions (our signature has 4), we counted a hit. We retrieved 5 hits over 50,000 iterations.

5. Acknowledgments

This work has been supported in part by the State of Florida's Consortium for Medical Marijuana Clinical Outcomes Research. Trial: NCT05209867. 10x single-cell RNA sequencing, including library preparation, was performed by the following UF ICBR Cores: Gene Expression & Genotyping (GE) RRID:SCR_019145, NextGen DNA Sequencing (NS) RRID:SCR_019152, Bioinformatics (BI) RRID:SCR_019120. We would like to thank The Southern HIV and Alcohol Research Consortium (SHARC) for the help provided with the recruitment.

6. References

1. Nasi, M. *et al.* Ageing and inflammation in patients with HIV infection. *Clin Exp Immunol* **187**, 44–52 (2017).
2. Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol* **15**, 505–522 (2018).
3. Andrade, V. M. *et al.* A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. *Proc Natl Acad Sci U S A* **117**, 9981–9990 (2020).
4. Vignoles, M. *et al.* Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses. *Journal of Virus Eradication* **7**, 100053 (2021).
5. Hendricks, C. M. *et al.* Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells. *Microbiology Spectrum* **10**, e01353-22 (2022).
6. Palmer, S. *et al.* Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. *Proc Natl Acad Sci U S A* **105**, 3879–3884 (2008).
7. Eisele, E. & Siliciano, R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. *Immunity* **37**,

- 377–388 (2012).
8. Stevenson, M. Role of myeloid cells in HIV-1-host interplay. *J. Neurovirol.* **21**, 242–248 (2015).
 9. Rodrigues, V., Ruffin, N., San-Roman, M. & Benaroch, P. Myeloid Cell Interaction with HIV: A Complex Relationship. *Frontiers in Immunology* **8**, (2017).
 10. Wong, M. E., Jaworowski, A. & Hearps, A. C. The HIV Reservoir in Monocytes and Macrophages. *Front Immunol* **10**, (2019).
 11. Merino, K. M., Allers, C., Didier, E. S. & Kuroda, M. J. Role of Monocyte/Macrophages during HIV/SIV Infection in Adult and Pediatric Acquired Immune Deficiency Syndrome. *Frontiers in Immunology* **8**, (2017).
 12. Liang, H., Xie, Z. & Shen, T. Monocyte activation and cardiovascular disease in HIV infection. *Cell Mol Immunol* **14**, 960–962 (2017).
 13. Marini, E. *et al.* HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. *Cell Microbiol* **10**, 655–666 (2008).
 14. Tenorio, A. R. *et al.* Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. *J Infect Dis* **210**, 1248–1259 (2014).
 15. Hunt, P. W. *et al.* Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. *J Infect Dis* **210**, 1228–1238 (2014).
 16. Atalay, S., Jarocka-Karpowicz, I. & Skrzydlewska, E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants* **9**, 21 (2020).
 17. Sunda, F. & Arowolo, A. A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol. *The FASEB Journal* **34**, 14083–14092 (2020).
 18. Burstein, S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. *Bioorganic & Medicinal Chemistry* **23**, 1377–1385 (2015).
 19. Costiniuk, C. T. & Jenabian, M.-A. Cannabinoids and inflammation: implications for people living with HIV. *AIDS* **33**, 2273–2288 (2019).
 20. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e29 (2021).
 21. Russo, R. C., Garcia, C. C., Teixeira, M. M. & Amaral, F. A. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. *Expert Rev Clin Immunol* **10**, 593–619 (2014).

22. Verma, V. *et al.* The dichotomous role of epiregulin in pain. *Pain* **161**, 1052–1064 (2020).
23. Veenhuis, R. T., Abreu, C. M., Shirk, E. N., Gama, L. & Clements, J. E. HIV replication and latency in monocytes and macrophages. *Seminars in Immunology* **51**, 101472 (2021).
24. Renoux, F. *et al.* The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development. *Cell Rep* **31**, 107826 (2020).
25. Liu, N. *et al.* Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes. *Cell Reports* **37**, 109793 (2021).
26. Blondin-Ladrie, L. *et al.* Monocyte Gene and Molecular Expression Profiles Suggest Distinct Effector and Regulatory Functions in Beninese HIV Highly Exposed Seronegative Female Commercial Sex Workers. *Viruses* **14**, 361 (2022).
27. Foo, C. X. *et al.* GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. *European Respiratory Journal* (2022) doi:10.1183/13993003.01306-2022.
28. Boucher, A. *et al.* The miR-23a~27a~24-2 microRNA Cluster Promotes Inflammatory Polarization of Macrophages. *The Journal of Immunology* **206**, 540–553 (2021).
29. Wu, F. *et al.* MicroRNAs Are Differentially Expressed in Ulcerative Colitis and Alter Expression of Macrophage Inflammatory Peptide-2 α . *Gastroenterology* **135**, 1624-1635.e24 (2008).
30. Kozaki, T. *et al.* Mitochondrial damage elicits a TCDD-inducible poly(ADP-ribose) polymerase-mediated antiviral response. *Proceedings of the National Academy of Sciences* **114**, 2681–2686 (2017).
31. Audrito, V., Messana, V. G. & Deaglio, S. NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. *Frontiers in Oncology* **10**, (2020).
32. Ren, K. & Torres, R. Role of interleukin-1 β during pain and inflammation. *Brain Res Rev* **60**, 57–64 (2009).
33. Henao-Mejia, J., Elinav, E., Strowig, T. & Flavell, R. A. Inflammasomes: far beyond inflammation. *Nat Immunol* **13**, 321–324 (2012).
34. Date, D. *et al.* Kruppel-like Transcription Factor 6 Regulates Inflammatory Macrophage Polarization *. *Journal of Biological Chemistry* **289**, 10318–10329 (2014).
35. Szklarczyk, D. *et al.* The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res* **49**, D605–D612

(2021).

36. Sparrow, E. & Bodman-Smith, M. D. Granulysin: The attractive side of a natural born killer. *Immunology Letters* **217**, 126–132 (2020).
37. Wang, X.-M. *et al.* Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection. *Cell Discov* **8**, 1–17 (2022).
38. Pauli, C. S., Conroy, M., Vanden Heuvel, B. D. & Park, S.-H. Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects. *Frontiers in Pharmacology* **11**, (2020).